183 related articles for article (PubMed ID: 30789856)
21. The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors.
Shen T; Jiang X; Jin Z; Ji Q; Li C; Li Q; Long H; Qiu W; Wang W; Hou X; You J
Eur J Pharm Biopharm; 2020 Apr; 149():135-144. PubMed ID: 32007590
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial.
Tan ND; Liu XW; Liu CX; Li SB; Chen HH; Li X; Wu H; Liao AJ; Zhen YB; Shen PZ; Huo LJ; Liu HL; Shi RH; Zhang BQ; Zhang ZY; Wang JN; Zhan Q; Deng H; Shu X; Tuo BG; Wang QZ; Du SY; Qi LZ; Zhang GX; Peng Q; Wang BM; Ye B; Chen MH; Xiao YL
J Gastroenterol Hepatol; 2022 Nov; 37(11):2060-2066. PubMed ID: 36068945
[TBL] [Abstract][Full Text] [Related]
23. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
24. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
25. [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
Gao W; Cheng H; Hu FL; Lü NH; Xie Y; Sheng JQ; Xu JM; Zhang LX; Zhang L; Chen Y; Zhang ZY; Zhang GX; Cui MH; Yang GB; Gao HJ; Yang L
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(30):2108-12. PubMed ID: 23158273
[TBL] [Abstract][Full Text] [Related]
26. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
27. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1998 Aug; 12(8):789-95. PubMed ID: 9726393
[TBL] [Abstract][Full Text] [Related]
28. Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer.
Park HJ; Kim HS; Kim BR; Park SY; Hong JH; Jo KW; Kim JW
Dig Dis Sci; 2013 Apr; 58(4):1054-61. PubMed ID: 23065090
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of rabeprazole once daily for acid-related disorders.
Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
[TBL] [Abstract][Full Text] [Related]
30. A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. European Pantoprazole Study Group.
Cremer M; Lambert R; Lamers CB; Delle Fave G; Maier C
Dig Dis Sci; 1995 Jun; 40(6):1360-4. PubMed ID: 7781461
[TBL] [Abstract][Full Text] [Related]
31. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.
Shu X; Zhu Z; Fu Y; Zhang Z; Wang J; Li X; He S; Fan H; Liu S; Zhang G; Tang J; Huang C; Du Q; Wang X; Xu B; Du Y; Chen Q; Wang B; Chen Y; Duan X; Xie Y; Huo L; Hou X; Lu N
Front Med (Lausanne); 2021; 8():690995. PubMed ID: 34336894
[No Abstract] [Full Text] [Related]
32. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
[TBL] [Abstract][Full Text] [Related]
33. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
James L; Walson P; Lomax K; Kao R; Varughese S; Reyes J;
Clin Ther; 2007 Sep; 29(9):2082-92. PubMed ID: 18035206
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Fujiwara S; Morita Y; Toyonaga T; Kawakami F; Itoh T; Yoshida M; Kutsumi H; Azuma T
J Gastroenterol; 2011 May; 46(5):595-602. PubMed ID: 21359522
[TBL] [Abstract][Full Text] [Related]
36. A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan.
Sugizaki K; Sakata Y; Arai T; Furuhata Y; Iinuma N; Suzuki H
Intern Med; 2012; 51(22):3103-8. PubMed ID: 23154713
[TBL] [Abstract][Full Text] [Related]
37. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
38. Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Di Mario F; Battaglia F; Dal Bò N; Leandro G; Benedetti E; Bottona E; Caroli A; Costan-Biedo F; De Bastiani R; Germanà B; Andrea Grassi S; Madia D; Marcon V; Marin R; Monica F; Olivieri P; Orzes N; Pilotto A; Ronzani G; Saggioro A; Tafner G
Dig Liver Dis; 2000 Mar; 32(2):108-15. PubMed ID: 10975783
[TBL] [Abstract][Full Text] [Related]
39. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
[TBL] [Abstract][Full Text] [Related]
40. Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
Johnson M; Guilford S; Libretto SE;
Curr Med Res Opin; 2002; 18(5):303-10. PubMed ID: 12240793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
